Merck & Co (NY:MRK)

139.90 -4.40 (-3.05%)

Delayed Quote Updated: 12:23 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2

...

19 20 21 22 23 24 25 26 27

...

99 100 Next >

Merck Enters into Research and Development Funding Agreement with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT)

November 04, 2025

From Merck & Co., Inc.

Via Business Wire

Merck Signs Agreement with Dr. Falk Pharma GmbH for Certain Development and Commercialization Rights to MK-8690 (PRA-052) an Investigational Anti-CD30 Ligand Monoclonal Antibody

November 04, 2025

From Merck & Co., Inc.

Via Business Wire

Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones? ↗

November 04, 2025

With yields of up to 7%, this trio of high-yield stocks are all industry-leading companies.

Via The Motley Fool

Topics Energy Stocks

Earnings Scheduled For October 30, 2025 ↗

October 30, 2025

Via Benzinga

Merck Foundation Launches $22 Million Initiative to Improve Cardiovascular Care in the U.S.

November 03, 2025

From Merck Sharp & Dohme

Via Business Wire

AI Unleashes a New Era: Biopharma’s Accelerated Revolution and the Rise of TechBio

November 01, 2025

The biopharmaceutical industry is undergoing an immediate and profound transformation, as Artificial Intelligence (AI) rapidly compresses timelines, drastically reduces costs, and significantly...

Via TokenRing AI

Topics Animal Testing Artificial Intelligence Economy

Amgen Solidifies Biotech Dividend Prowess with $2.38 Q4 2025 Payout

October 31, 2025

Thousand Oaks, CA – October 31, 2025 – Amgen (NASDAQ: AMGN), a leading biotechnology giant, has declared a quarterly dividend of $2.38 per share for the fourth quarter of 2025. This significant...

Via MarketMinute

Topics Intellectual Property

AI Revolutionizes Pharma: Smarter Excipients for Safer, More Potent Drugs

October 31, 2025

San Francisco, CA – October 31, 2025 – Artificial intelligence (AI) is ushering in a transformative era for the pharmaceutical industry, particularly in the often-overlooked yet critical domain of...

Via TokenRing AI

Topics Artificial Intelligence Supply Chain

AI: The Pharmaceutical Sector’s New Catalyst for a Healthier Future

October 31, 2025

The pharmaceutical industry is in the midst of a profound and rapid transformation, driven by the pervasive integration of Artificial Intelligence (AI). What was once a futuristic concept is, by late...

Via TokenRing AI

Topics Animal Testing Artificial Intelligence Economy

Merck Q3 2025 Earnings Call Transcript ↗

October 31, 2025

Merck Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain ↗

October 30, 2025

As Eli Lilly, Novo Nordisk, and Pfizer battle for dominance in the obesity-drug market, these ETFs are offering exposure to the GLP-1 gold rush.

Via Benzinga

Topics ETFs

Merck Ready For Larger Than $15 Billion Deals, Raises Annual Profit Outlook ↗

October 30, 2025

Merck shares dipped after strong earnings and higher profit guidance, as the company narrowed its 2025 sales forecast amid mixed product performance.

Via Benzinga

Merck’s (NYSE:MRK) Q3 Sales Top Estimates

October 30, 2025

Global pharmaceutical company Merck (NYSE:MRK) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 3.7% year on year to $17.28 billion. The company expects the full year’s revenue to be...

Via StockStory

Meta Tumbles 10%, Google Marks Historic Rally: What's Moving Markets Thursday? ↗

October 30, 2025

Wall Street saw a cautious tone on Thursday as major tech-heavy indexes edged lower, weighed down by mixed earnings from the mega-caps and the lingering impact of hawkish remarks from Fed Chair Jerome...

Via Benzinga

Topics Economy

Merck & Co. Inc. (NYSE:MRK) Q3 2025 Earnings Beat Expectations Despite Stock Decline ↗

October 30, 2025

Merck Q3 2025 earnings beat estimates with strong sales and EPS growth, driven by KEYTRUDA and WINREVAIR, yet shares fell on guidance.

Via Chartmill

Topics Earnings

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields ↗

October 30, 2025

Via Benzinga

Dow Jones Stock Merck Tops Expectations, But Gardasil Challenges Remain ↗

October 30, 2025

The company sells a notable vaccine to prevent human papillomavirus. But sales are struggling.

Via Investor's Business Daily

Topics Earnings Stocks

Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results

October 30, 2025

From Merck & Co., Inc.

Via Business Wire

Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability

October 29, 2025

Via Investor Brand Network

Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma

October 29, 2025

From Merck & Co., Inc.

Via Business Wire

European Commission Approves KEYTRUDA® (pembrolizumab) as Part of a Treatment Regimen for Adults with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Expressing PD-L1 (CPS >1)

October 29, 2025

From Merck & Co., Inc.

Via Business Wire

Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability

October 29, 2025

EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOVA),(NYSE:MRK),(NYSE:LLY),(NYSE:JNJ) EQNX::TICKER_END

Via FinancialNewsMedia

Merck (MRK) Reports Earnings Tomorrow: What To Expect

October 28, 2025

Global pharmaceutical company Merck (NYSE:MRK) will be reporting earnings this Thursday morning. Here’s what you need to know.

Via StockStory

Topics Artificial Intelligence

Looking At Merck & Co's Recent Unusual Options Activity ↗

October 28, 2025

Via Benzinga

Merck's New Cancer Therapy Combo Shows Significant Edge Over Rivals In Renal Cancer ↗

October 28, 2025

Merck and Eisai report Phase 3 results showing Welireg plus Lenvima significantly improved progression-free survival in advanced kidney cancer.

Via Benzinga

Merck Announces KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Clear Cell Renal Cell Carcinoma (RCC) Following Nephrectomy

October 28, 2025

From Merck & Co., Inc.

Via Business Wire

Merck and Eisai Announce WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma

October 28, 2025

From Merck & Co., Inc.

Via Business Wire

Healthcare Sector Navigates Volatile Waters as S&P 500 Closes: A Deep Dive into Key Market Drivers

October 27, 2025

As the closing bell rings on October 27, 2025, the S&P 500 Healthcare sector stands at a critical juncture, exhibiting the nuanced volatility that defines this essential yet complex segment of the...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

3 Dividend-Paying Drug Stocks to Buy at a Discount ↗

October 27, 2025

Some of the largest drugmakers in the world are trading at attractive valuations. Are they worth buying?

Via The Motley Fool

Topics Intellectual Property

How Is The Market Feeling About Merck & Co Inc? ↗

October 27, 2025

Via Benzinga

< Previous 1 2

...

19 20 21 22 23 24 25 26 27

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.